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Received August 7, 2014; accepted January 30, 2015AbstractBackground: High-grade malignant mixed adenoneuroendocrine carcinoma (MANEC) is a highly malignant combined neoplasm formed by an
adenocarcinomatous component and a poorly differentiated (Grade 3) neuroendocrine (NE) carcinoma.
Methods: Tumors from 21 patients with gastrointestinal high-grade malignant MANECs or tumors with varying percentages of Grade 3 NE
component were examined, and the NE component was confirmed by morphological analysis and immunohistochemical staining. Patients were
divided into high NE (NE component > 50% in the primary tumor) and low NE (NE component  50% in the primary tumor) component
groups.
Results: High NE component was a poor prognostic factor for patients with high grade MANEC ( p ¼ 0.021). Out of 13 patients with high-grade
malignant MANEC, eight had a pure NE component, one had a pure adenocarcinomatous component, and four had mixed-type cancer in the
metastatic lymph nodes. We further enrolled eight patients who had a Grade 3 NE component in the primary tumor and found that the pure NE
component in tumor emboli and distant liver metastases were more frequent in the high NE than in the low NE component group ( p ¼ 0.012 and
p ¼ 0.046, respectively).
Conclusion: The predominant tumor component in primary tumors was a prognostic factor and could predict tumor emboli and liver metastases
pathology in high-grade malignant MANECs.
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Human cancers with a combination of neuroendocrine (NE)
and exocrine features are known to occur in various organs
such as the prostate,1 breast,2,3 colon,4 stomach,5e8 and lungs.9
This spectrum of tumors shows mixed divergent differentiation
along NE and exocrine lineages; these two components exhibit
variable proportion, ranging from 1% to 99%. From theseociation. All rights reserved.
Table 1
Univariate analysis of factors influencing the overall survival (OS) of 21 high-
grade mixed adenoneuroendocrine tumor patients.a
Characteristics No. of patients
(n ¼ 21)
Median
OS (mo)
p
Age, (y) 0.819
 65 14 (66.7) 15.4
< 65 7 (33.3) 24.9
Sex 0.396
Male 14 (66.7) 24.7
Female 7 (33.3) 12.0
Tumor origin 0.711
Stomach 16 (76.2) 24.7
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are defined as malignant tumors characterized by morpho-
logically recognizable gland-forming epithelial and NE com-
ponents, with at least 30% of either component being present
in the tumor, according to the World Health Organization
(WHO) classification of endocrine tumors of the digestive
system.10
MANECs are very rare cancers,11,12 and can be divided into
low, intermediate, and high grades of malignancy. The optimal
strategy for managing MANEC is unknown, due to the rarity
of these neoplasms. In general, MANECs containing a low-
grade NE tumor component and an adenocarcinomatous
component should be treated as adenocarcinoma.13e15 Tumors
containing a high-grade NE component should be treated as
NEC.13e15
It is interesting that the extent of these two components in
primary tumors and lymph nodes is not always the same.5,6
One report presented a case of gastric MANEC, in which
the neoplastic signet-ring cell exocrine and NE components
occurred in fairly equivalent amounts, with only the NE car-
cinoma portions of the tumor detected in the metastatic lymph
nodes.5 Distant metastasis to vital organs is the main cause of
death from cancer. Thus, it is worth investigating the tumor
components in the lymph nodes and distant metastases of
patients with MANEC, which may help clinicians to adopt
different treatment strategies.
In this study, we retrospectively enrolled 13 patients with
high-grade malignant MANEC and observed the pathology of
the primary tumor, tumor emboli, lymph nodes, and distant
liver metastases. Eight patients had a pure NE component, one
patient had an adenocarcinomatous component, and four pa-
tients had a mixed-type cancer in the metastatic lymph nodes.
We further enrolled another eight patients who had a Grade 3
NE component in the primary tumor. Of the eight patients, the
proportion of the NE component was > 70% in five patients,
and < 30% in three patients. We identified that the high NE
component in the primary tumor was a factor for poor prog-
nosis and also could predict the pathology of tumor emboli
and distant liver metastases in high-grade MANECs.
2. Methods
Gall bladder 2 (9.5) 5.0
Colon 3 (14.3) 10.7
Adenocarcinoma grading 0.218
2.1. Patient clinicopathological dataG1 5 (23.8) 15.4
G2 14 (66.7) 24.9
G3 2 (9.5) 1.4
Neuroendocrine component (%) 0.021
> 50 13 (61.9) 10.7
 50 8 (38.1) Not reached
Chemotherapy 0.635
Yes 10 (47.6) 24.7
No 11 (52.4) 15.4
AJCC staging 0.455
I þ II 5 (23.8) Not reached
III þ IV 16 (76.2) 12.0
Bold value signifies p < 0.05.
Data are presented as n (%).
AJCC ¼ American Joint Committee on Cancer.
a World Health Organization classification [9].This study was approved by the Ethics Committee of the
Taipei Veterans General Hospital, Taipei, Taiwan and the
National Taiwan University Hospital, Taipei, Taiwan. Clinical
data and pathological data were obtained through a detailed
retrospective review of the medical records for 13 patients
with MANEC between 2000 and 2010 at the Taipei Veterans
General Hospital and the National Taiwan University Hospital.
All patients underwent surgery. The median age of the patients
was 76 years (range, 55e84 years). The origin of the primary
tumor differed between patients; the primary tumor site was
the stomach in nine patients, the colon in three, and the gall
bladder in one. Follow-up data were available in all cases, and
the duration of follow-up was 0.8e49.7 months (median, 15.9months; mean, 18.6 months). The last survival data were
collected on December 31, 2013. We also enrolled another
eight patients whose tumors had Grade 3 NE components. The
percentage of the NE component was > 70% in five patients
and < 30% in three patients. The characteristics of 21 cases
are summarized in Table 1.2.2. Immunohistochemical stainingHematoxylin and eosin staining results of all 21 samples
were reviewed by two pathologists. The specimens were fixed
in formalin and embedded in paraffin before they were
archived. We used the archived specimens for immunohisto-
chemical analysis. Immunohistochemical staining was per-
formed with Bond-Max autostainer (Leica Microsystems,
Wetzlar, Germany), using CD56 (NCL-CD56-1B6, clone 1B6;
1:15; Novocastra/Leica, Newcastle-upon-Tyne, UK), chro-
mogranin (NCL-CHROM-430, clone 5H7; 1:50; Novocastra/
Leica), synaptophysin (NCL-SYNAP-299, clone 27G12; 1:50;
Novocastra/Leica), and neuron-specific enolase (BBS/NC/VI-
H14; 1:200; Dako, Carpinteria, CA, USA). Briefly, specimens
from the paraffin-embedded blocks were cut into 5-mm sec-
tions. The sections were dewaxed in a 60C oven, deparaffi-
nized in xylene, rehydrated through serial dilutions of alcohol,
and washed in phosphate-buffered saline (pH 7.2). Immuno-
histochemical staining was performed in the fully automated
Bond-Max autostainer using onboard, heat-induced antigen
retrieval in citrate buffer according to the ER1 protocol for 20
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Microsystems). Diaminobenzidine was used as the chromogen
(Leica Microsystems). The sections were then counterstained
with hematoxylin.2.3. Evaluation of the NE component in primary tumors,
tumor emboli, lymph nodes, and distant liver metastasesThe percentage of the NE component in primary tumors,
status of tumor spreading, and the tumor component in tumor
emboli, lymph nodes or liver metastases were evaluated by
two pathologists. In primary tumors, the NE component was
confirmed by morphology and positive immunohistochemical
staining for two of the four NE markers (CD56, chromogranin,
synaptophysin, and neuron-specific enolase).
For tumors found in tumor emboli, lymph nodes, and liver
metastases, the NE component was confirmed by morphology
alone, the results of which were then compared with that of
primary tumors. Cases of adenocarcinoma showing focal NE
differentiation were identified only by immunostaining and not
by morphological differences; amphicrine tumors thus iden-
tified were excluded from the study.2.4. Statistical analysisWe divided the patients into two groups: the high NE-
component group (n ¼ 13; defined by an NE component of
> 50% in the primary tumor) and the low NE-component
group (n ¼ 8; defined by an NE component of  50% in
the primary tumor). The association between the proportion of
NE component in primary tumors and in tumor emboli or
lymph node or distant liver metastases was analyzed for sta-
tistical significance using the Chi-square test. Survival data
were analyzed according to the KaplaneMeier method. The
log-rank test was used to compare survival data between
groups. A p value of < 0.05 was considered significant.
3. Results3.1. High NE components in primary MANEC was
associated with poor prognosisUnivariate overall survival analysis was performed to test
the prognostic significance of clinical variables in 21 MANEC
cases, and only NE components in primary tumor was shown
to have an adverse impact on survival ( p ¼ 0.021; Table 1 and
Fig. 1). Our data indicate that high NE components in primary
tumor predicted a poor prognosis in terms of high-grade
MANEC.3.2. Pathology of tumors involved in tumor emboli was
similar to that in metastatic lymph nodes and distant
liver metastasesOf the 21 patients, 20 had tumor emboli, 17 had metastatic
lymph nodes, and four had distant liver metastases. Pure NE
sections in tumor emboli were observed in 13 patients, pureadenocarcinoma was observed in four patients, and both
components were observed in three patients (Table 2). In
most cases, the components of lymph node metastases and
distant liver metastases were similar to those of tumor
emboli; only two patients had different components (Cases 2
and 9, Table 2).
Therefore, the tumor components involved in tumor emboli
may suggest the pathology of metastatic lymph nodes and
distant liver metastases (Table 2).3.3. Increased percentage of pure NE component tumors
in tumor emboli and distant liver metastases in the high
NE component groupNext, we divided the patients into two groups: the high NE
component group with patients showing > 50% NE compo-
nent in the primary tumor (n ¼ 13) and the low NE component
group with patients showing  50% NE component in the
primary tumor (n ¼ 8; Table 3). In cases of tumor emboli,
91.7% (11/12) of patients in the high NE group had a pure NE
component in their tumors, whereas 50% (4/8) of patients in
the low NE group had a pure adenocarcinomatous component.
In cases of distant liver metastases, 100% (3/3) of patients in
the high NE group had a pure NE component in their tumors,
whereas 100% (1/1) of patients in the low NE group had a pure
adenocarcinomatous component. From these results, we
observed that tumor emboli and distant liver metastases with a
pure NE component were observed more frequently in the
high NE component group than in the low NE component
group ( p ¼ 0.012 and p ¼ 0.046; Table 3).3.4. Increased percentage of pure NE-component tumors
in lymph nodes in high NE component groupIn cases of lymph nodes, 81.8% (9/11) of patients in the
high NE component group showed pure NE-component tu-
mors in their lesions of lymph nodes, whereas 33.3% (2/6) of
patients in the low NE component group showed pure
adenocarcinomatous component tumors. These data show that
pure NE-component tumors in lymph nodes showed more of a
trend in the high NE component group than in the low NE
component group ( p ¼ 0.065; Table 3).
4. Discussion
Gastrointestinal MANECs can be stratified into three
different prognostic categories according to the grade of each
component's malignancy.16 High-grade malignant MANEC is
a highly malignant combined neoplasm formed by an adeno-
matous (villous or tubulovillous) or carcinomatous (adeno-
carcinoma or squamous cell carcinoma) component, together
with a poorly differentiated (Grade 3) NEC.15 The optimal
treatment strategy for high-grade malignant MANEC is un-
known because of the rarity of the disease. When considering
treatment, the more aggressive component of MANECs should
be taken into account. MANEC containing a well differenti-
ated NET (Grades 1 or 2) component and an adenocarcinoma
Table 2
The relationship between the pathology of tumor emboli, regional lymph node, and distant liver metastasis.
Case NE component (%) Ki67 Diagnosis WHO grading of adenocarcinoma Tumor emboli Lymph nodes Distant liver metastasis
1 30 d MANEC 2 Ad Ad Ad
2 30 d MANEC 2 Ad NE d
3 40 d MANEC 2 NE NE d
4 50 d MANEC 3 Ad þ NE Ad þ NE d
5 50 d MANEC 2 Ad þ NE Ad þ NE d
6 60 80 MANEC 2 NE NE NE
7 60 d MANEC 2 NE NE d
8 60 70 MANEC 1 Ad þ NE Ad þ NE d
9 60 d MANEC 1 NE Ad þ NE NE
10 70 d MANEC 1 NE NE d
11 70 90 MANEC 3 NE NE d
12 70 d MANEC 2 NE NE d
13 70 d MANEC 2 NE NE dE
14 80 80 NEC 1 NE d d
15 80 d NEC 2 NE NE d
16 80 90 NEC 1 d d d
17 90 d NEC 2 NE NE d
18 95 70 NEC 2 NE NE d
19 10 d Ad 2 Ad d d
20 15 d Ad 2 Ad Ad d
21 20 d Ad 2 NE d d
Ad ¼ adenocarcinoma; MANEC ¼ mixed adenoneuroendocrine tumor; NE ¼ neuroendocrine tumor; NEC ¼ neuroendocrine carcinoma.
Table 3
A high neuroendocrine component in primary mixed neuroendocrine tumors resulted in the development of a pure neuroendocrine component in tumor emboli,
lymph node, or distant liver metastasis.
Tumor emboli Regional lymph node Distant liver metastasis
NE Ad Both p NE Ad Both p NE Ad Both p
Neuroendocrine component (%)
 50 2 4 2 0.012 2 2 2 0.065 0 1 0 0.046
> 50 11 0 1 9 0 2 3 0 0
Ad ¼ adenocarcinoma; NE ¼ neuroendocrine tumor.
Fig. 1. (A and B) Tumor showing both adenocarcinomatous (arrow) and neuroendocrine (NE) components (arrowhead); the chromogranin stain highlights the NE-
component portion of the tissue. (C) KaplaneMeier plot of the overall survival of 21 patients with high grade MANEC, stratified by NE components in the primary
tumor.
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containing a poorly differentiated NEC (Grade 3) component
should be treated as NEC,13e15 although this recommendation
lacks enough evidence to support it. In our study, 75% (3/4) of
patients with high-grade malignant MANEC had a pure NE
component and 25% (1/4) had a pure adenocarcinomatous
component in distant liver metastases. Distant metastasis to
vital organs is the main cause of death from cancer. Thus, it is
reasonable to identify the tumor components in the distant
metastatic tumor of patients with MANEC, which may help
clinicians develop new treatment strategies.
In 1987, Lewin2 presented a method for classifying mixed-
type adenoneuroendocrine carcinomas according to three
separate patterns: (1) the exocrine and endocrine areas are
admixed within the same tumor mass and constitute at least
one-third of the tumor; (2) concurrent NE and exocrine dif-
ferentiation are exhibited by the same tumor cells, i.e.,
amphicrine tumors; and (3) the exocrine and endocrine areas
are juxtaposed, but not admixed within the same tumor mass.2
This study defined the criteria for determining the extent of the
NE component in mixed-type adenoneuroendocrine carci-
nomas as 30%, which incidentally, is the same as that
currently used.2,10 However, the significance of the NE
component in MANEC is unclear and has received limited
clinical attention.11 In this study, we wanted to investigate the
role of NE component in these patients. Thus, we recruited an
additional eight patients (3 patients with NE < 30% and 5
patients with NE > 70%) with varying NE components. We
enrolled a total of 21 patients with a poorly differentiated
(Grade 3) NEC component, at various percentages ranging
from 10% to 90%. We found that a high NE component (>
50%) in the primary tumor was associated with poor prog-
nosis. This phenomenon is also observed in prostatic adeno-
carcinomas with NE differentiation, which shows that the NE
component is a negative prognostic factor.17,18 We also found
high NE component increased rate of pure NE component
tumors in tumor emboli and distant liver metastases (Table 3).
The tumor components of the distant metastases should be the
main factor that affects tumor progression. However, it is
sometimes difficult to obtain tissue samples from metastatic
lesions. In this situation, the results of our study lead us to
suggest that the pathology of metastatic lesions can be deter-
mined by observing the components present in tumor emboli
or the percentage of the NE component in the primary tumor.
A high NE component was associated with an adverse
outcome and increased rate of pure NE component in distant
liver metastases. The negative prognostic value of a high NE
component of high-grade gastrointestinal MANECs might be
due to the clinical course of these diseases being more likely to
be pure poorly differentiated NE carcinomas.19
Most gastrointestinal MANECs generally show nuclear
immunoreactivity for CDX2. However, some reports also
showed CDX2 also expressed in small number of lung NE
carcinomas.20,21 In addition, La Rosa et al20 further subdivided
colorectal MANEC into four groups according to CDX2,
TTF1, and ASH1 expression. The expression of these tran-
scription factors does not show a prognostic significance, buttheir expression is interesting because it indicates the pheno-
typical heterogeneity of the neuroendocrine component of
gastrointestinal MANEC. Another interesting issue is the
possible mechanisms of two different components of cancer
cells coexisting in one tumor. There are two major hypotheses:
these tumors might arise independently from different stem/
progenitor cells, or they might derive from a common, mul-
tipotent stem/progenitor cell.13,15 Recently, Scardoni et al22
used next-generation sequencing to assess 54 cancer-
associated genes in patients with MANECs. Both the
exocrine and neuroendocrine components of six MANECs
were microdissected and analyzed. They found that five of the
six MANECs presented an overlapping mutational profile in
both components. The result suggested two different compo-
nents from the same stem/progenitor cell.
Neuron-specific enolase and chromogranin A are both
biomarkers of neuroendocrine neoplasms that have potential to
predict the outcome or monitor the treatment response.
However, the relationship of these biomarkers in MANEC is
still not clear. It warrants further studies in the future.
The main limitation of this study is its small sample size
(n ¼ 21). Also, MANEC is a very rare malignancy, and most
patients are diagnosed with distant metastases. Both of the
reasons mentioned above cause difficulties in the collection of
samples for analysis. Further studies are required to validate
the role of NE components in high-grade malignant MANEC.
In conclusion, we found that the extent of NE and adeno-
carcinomatous components in primary high-grade malignant
MANECs and their metastatic tumors are not always the same.
Furthermore, the NE component of tumors involved in tumor
emboli was similar with that in lymph node and distant liver
metastases. A high NE component in the primary tumor pre-
dicted a poor prognosis and increased the rate of pure NE
component tumors in tumor emboli or distant metastases.
These data may assist clinicians in deciding the appropriate
treatment method for patients with high-grade malignant
MANEC.
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